A comparison of radiographic signs of pulmonary inflammation during ECMO between silicon and poly-methyl pentene oxygenators

Abstract

Introduction: The inflammatory response caused by extracorporeal membrane oxygenation (ECMO) is clearly visible within the first 24 h of cannulation. The inflammatory process affects all areas of the lung, even areas previously spared by the primary disease. Objective: To compare the change in the radiographic signs of inflammatory response to ECMO between poly-methyl pentene and silicon oxygenators. Study design: Retrospective review of neonates and adults pre- and post-replacement of silicon oxygenators with poly-methyl pentene devices. Data were collected from Extracorporeal Life Support Organisation (ELSO) registry forms and patient records. Results were analysed by quantitative and semi-quantitative methods. Results: There was a significant reduction in the radiographic signs of inflammatory response to ECMO, and a reduction in the time taken to revert to pre-ECMO state in the neonatal poly-methyl pentene group compared to silicon. However, there was no significant reduction in the duration of ECMO runs and the percentage survival between these groups in the neonates. In adults, there was no difference in severity of radiographic signs between groups. However, the inflammatory changes were relatively delayed in the adult poly-methyl pentene group. Conclusion: Poly-methyl pentene (Medos) oxygenators have reduced the host's response phenomenon `white out' in neonates, and caused a delayed response in adults. This is most likely a consequence of smaller blood contact surface area combined with the effect of heparin coating of the oxygenator membrane. However, recovery was not a function of the type of gas exchange device used. Perfusion (2007) 22, 15-21.

Get full access to this article

View all access options for this article.

References

Stewart DL , Dela Cruz TV, Ziegler C, Goldsmith LJ. The use of extracorporeal membrane oxygenation in patients with gram-negative or viral sepsis. Perfusion 1997; 12(1): 3-8.

Plotz FB , van Oeveren W. , Bartlett RH , Wildevuur CR Blood activation during neonatal extracorporeal life support. J Thorac Cardiovasc Surg 1993; 105: 823-32.

Moat NE , Shore DF , Evans TW Organ dysfunction and cardiopulmonary bypass: the role of complements and complement regulatory proteins. Eur J Cardiothorac Surg 1993; 7: 563-73.

Maurer J. , Kendzia A. , Gerlach H. , Pappert D. , Hierholzer J. , Falke Kjr. Morphological changes in chest radiographs of patients with respiratory distress syndrome. Intensive Care Med 1998 ; 24(11): 1152-56.

Buchwald D. Extrakorporale zirkulation in theorie und praxis. In RJ Tschaut ed. Extrakorporeale membraoxygenation bei erwachsenen patientten. Pabst Science, 1999: S567-89.

Henseler A. , Oedekoven B. , Mottaghy K. Differentiated view of the pressure ratios in membrane oxygenation and heat exchangers. Kardiotechnik 2000; 9: S42-46.

Peek GJ , Killer HM , Reeves R. , Sosnowski AW , Firmin RK Early experience with a poly-methyl pentene oxygenator for adult extracorporeal life support. ASAIO J 2002; 48(5): 480-82.

Khoshbin E. , Machin D. , Killer H. et al. Improved gas exchange capability and reduction in transfusion requirements by using poly-methyl pentene oxygenators for adult extra-corporeal membrane oxygenation. ASAIO J 2005; 51(3): 281-87.

Khoshbin E. , Peek G. , Sosnowski AW et al. Performance of poly-methyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicon membrane oxygenators . Perfusion 2004; 20(3): 129-34.

10.

Mueller X. , Tevaearai H. , Jegger D. , Boone Y. , Augstburger M. , von Segesser L. Impact of hollow-fiber membrane surface area on oxygenator performance: Dideco D903 Avant versus a prototype with larger surface area. JECT 2000; 32(3): 152-57.

11.

Bramson ML , Osborn JJ , Main FB , O'Brian MF , Wright JS , Gerbode F. A new disposable membrane oxygenator with integral heat exchange. J Thorac Cardiovasc Surg 1965; 50(3): 391-400.

12.

Peek GJ , Firmin RK The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999; 45(4): 250-63.

13.

Ovrum E. , Tangen G. , Ringdal MA , Istad R. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery. J Cardiac Surg 2003; 18(2): 140-46.

14.

Tong SD , Rolfs MR , Hsu LC Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits . Trans ASAIO 1990; 36: 654-56.

15.

Pradhan MJ , Fleming JS , Nkere UU , Arnold J, Wildevuur ChRH, Taylor KM. Clinical experience with heparin-coated cardio-pulmonary bypass circuit. Perfusion 1991; 6(3): 235-42.

16.

Ranucci M. , Cazzaniga A. , Soro G. , Isgro G. , Frigiola A. , Menicanti L. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. [Clinical trial. Journal article. Randomised controlled trial]. J Cardiothorac Vasc Anesth 2002; 6(3): 316-20.

17.

Svenmarker S. , Sandstrom E. , Karlsson T. et al. Neurological and general outcome in low-risk coronary artery bypass patients using heparin-coated circuits. [Clinical trial. Evaluation studies. Journal article. Randomised controlled trial]. Eur J Cardiothorac Surg 2001; 19(1): 47-53.

18.

Beckley P. , Morris SM , Smith JJ , Mcnamara JL , Novak JA Comparison of the characteristics of three generations of membrane oxygenators: the Univox, Univox Gold and Spiral Gold. Perfusion 1996; 11(1): 61-70.

19.

Videm V. , Mollnes TE , Garred P. et al. Biocompatibility of extracorporeal circulation: in vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1999; 101: 654-60.

20.

Videm V. , Svennevig JL , Fosse E. et al. Reduced compliment activation with heparin-coated oxygenator and tubing in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 806-13.

21.

Pekna M. , Hagman L. , Halden E. et al. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994 ; 58: 421-24.

22.

Ovrum E. , Mollnes TE , Fosse E. et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg 1995; 60: 1755-61.

23.

Plotz FB , Van Oeveren W , Hultquist KA et al. A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. Artif Organ 1992; 16: 366-70.

24.

Te Velthuis H. , Jansen Pgm , Hack CE et al. Specific complement inhibition with heparin-coated extracorporeal circuits. Ann Thorac Surg 1996; 61: 1153-57.

25.

Fosse E. , Moen O. , Johnson E. et al. Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994 : 58: 472-77.

26.

Brovic J. , Thelin S. , Bagge L. et al. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1992; 104: 642-47.

27.

Gorman RC , Ziats NP , Rao AK et al. Surface bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 111: 1-12.

28.

Hatori N. , Yoshizu H. , Haga Y. et al. Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass. Artif Organs 1994; 18: 904-10.

29.

Peek GJ , Firmin RK The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999; 45(4): 250-63.

30.

Gu YJ , van Oeveren W. , Akkerman C. et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993 ; 55: 917-22.

31.

Redmond JM , Gilinov AM , Stuart RS et al. Heparin-coated bypass circuits reduce pulmonary injury. Ann Thorac Surg 1993; 56: 474-79.

32.

Weewind PW , Maessen JG , van Tits Ljh et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. J Thorac Cardiovasc Surg 1995; 110: 1633-41.

33.

Hogevold HE , Moen O. , Fosse E. et al. Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leukocytes in extracorporeal circulation in vitro . Perfusion 1997; 12: 9-20.

34.

Ranucci M. , Cirri S. , Conti D. et al. Beneficial effects of Duraflo II heparin-coated circuits on post perfusion lung dysfunction. Ann Thorac Surg 1996; 61: 76-81.